Customization of biliopancreatic limb length to modulate and sustain antidiabetic effect of gastric bypass surgery.

A Pal
A Pal
Saha Institute of Nuclear Physics

Am J Physiol Gastrointest Liver Physiol 2018 02 2;314(2):G287-G299. Epub 2017 Nov 2.

Department of Surgery, Brigham and Women's Hospital , Boston, Massachusetts.

Although Roux-en-Y Gastric Bypass (RYGB) remains the most effective treatment for obesity and type 2 diabetes (T2D), many patients fail to achieve remission, or relapse. Increasing intestinal limb lengths of RYGB may improve outcomes, but the mechanistic basis for this remains unclear. We hypothesize biliopancreatic (BP) limb length modulates the antidiabetic effect of RYGB. Rats underwent RYGB with a 20-cm (RYGB-20cm) or 40-cm (RYGB-40cm) BP limb and were compared with control animals. After 2 and 4 wk, portal and systemic blood was sampled during intestinal glucose infusion. Portosystemic gradient was used to calculate intestinal glucose utilization (G), absorption (G), and hormone secretion. Intestinal morphology and gene expression were assessed. At 2 wk, G progressively decreased with increasing BP limb length; this pattern persisted at 4 wk. G increased ≈70% in both RYGB-20cm and -40cm groups at 2 wk. At 4 wk, G progressively increased with limb length. Furthermore, Roux limb weight, and expression of hexokinase and preproglucagon, exhibited a similar progressive increase. At 4 wk, glucagon-like peptide-1 and -2 levels were higher after RYGB-40cm, with associated increased secretion. We conclude that BP limb length modulates multiple antidiabetic mechanisms, analogous to the dose-response relationship of a drug. Early postoperatively, a longer BP limb reduces G. Later, G, Roux limb hypertrophy, hormone secretion, and hormone levels are increased with longer BP limb. Sustained high incretin levels may prevent weight regain and T2D relapse. These data provide the basis for customizing BP limb length according to patient characteristics and desired metabolic effect. NEW & NOTEWORTHY Biliopancreatic limb length in gastric bypass modulates multiple antidiabetic mechanisms, analogous to the dose-response relationship of a drug. With a longer biliopancreatic limb, Roux limb hypertrophy, increased glucose utilization, reduced glucose absorption, and sustained high incretin levels may prevent weight regain and diabetes relapse.

Download full-text PDF

Source Listing
February 2018
13 Reads

Publication Analysis

Top Keywords

limb length
biliopancreatic limb
gastric bypass
roux limb
limb hypertrophy
longer limb
sustained high
incretin levels
prevent weight
levels prevent
relationship drug
high incretin
antidiabetic mechanisms
hormone secretion
glucose utilization
intestinal glucose
length modulates
modulates multiple
mechanisms analogous

Similar Publications

Intestinal sweet-sensing pathways and metabolic changes after Roux-en-Y gastric bypass surgery.

Am J Physiol Gastrointest Liver Physiol 2014 Sep 3;307(5):G588-93. Epub 2014 Jul 3.

Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts;

Studies suggest that improvements in type 2 diabetes (T2D) post- Roux-en-Y gastric bypass (RYGB) surgery are attributable to decreased intestinal glucose absorption capacity mediated by exclusion of sweet taste-sensing pathways in isolated proximal bowel. We probed these pathways in rat models that had undergone RYGB with catheter placement in the biliopancreatic (BP) limb to permit post-RYGB exposure of isolated bowel to sweet taste stimulants. Lean Sprague Dawley (n = 13) and obese Zucker diabetic fatty rats (n = 15) underwent RYGB with BP catheter placement. Read More

View Article
September 2014

Should Roux-en-Y gastric bypass biliopancreatic limb length be tailored to achieve improved diabetes outcomes?

Medicine (Baltimore) 2017 Dec;96(48):e8859

Department of General Surgery, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira.

The objective is to access the role of Roux-en-Y gastric bypass (RYGB) biliopancreatic limb (BPL) length in type 2 diabetes (T2D) outcomes.RYGB is more effective than medical intervention for T2D treatment in obese patients. Despite the scarcity of available data, previous reports suggest that modifications of the RYGB limb lengths could improve the antidiabetic effects of the surgery. Read More

View Article
December 2017

Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass.

Dan Med J 2015 Apr;62(4):B5057

Department of Endocrinology, Hvidovre Hospital, Kettegårds Alle, 2650 Hvidovre. Denmark.

Roux-en-Y gastric bypass (RYGB) surgery induces weight loss of 20-30% that is maintained for 20 years. In patients with type 2 diabetes, the glucose-lowering effect of RYGB is superior to conventional antidiabetic therapy and often occurs within days after surgery. The aim of the thesis was to investigate the physiological mechanisms responsible for improved glycaemic control with special focus on the early postoperative period. Read More

View Article
April 2015

A Prospective Single-Arm Trial of Modified Long Biliopancreatic and Short Alimentary Limbs Roux-En-Y Gastric Bypass in Type 2 Diabetes Patients with Mild Obesity.

Obes Surg 2018 Mar;28(3):599-605

Center for Bariatric and Metabolic Surgery, São Domingos Hospital, São Luís, Brazil.

Background: Type-2 diabetes (T2D) patients with body mass index (BMI) below 35 kg/m carry lower remission rates than severely obese T2D individuals submitted to "standard limb lengths" Roux-en-Y gastric bypass (RYGB). Mild-obese patients appear to have more severe forms of T2D, where the mechanisms of glycemic control after a standard-RYGB may be insufficient. The elongation of the biliopancreatic limb may lead to greater stimulation of the distal intestine, alterations in bile acids and intestinal microbiota, among other mechanisms, leading to better metabolic outcomes. Read More

View Article
March 2018